债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于健帆转债回售的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300529 证券简称：健帆生物 公告编号：2025-050 根据《募集说明书》，有条件回售条款的约定如下： 1、有条件回售条款 本次发行的可转债最后两个计息年度内，如果公司股票在任意连续三十个交 易日的收盘价格低于当期转股价格的 70%，可转债持有人有权将其持有的可转 债全部或部分按债券面值加上当期应计利息的价格回售给公司。 若在上述交易日内发生过转股价格因发生派送股票股利、转增股本、增发新 股（不包括因本次发行的可转债转股而增加的股本）、配股以及派发现金股利等 情况而调整的情形，则在调整前的交易日按调整前的转股价格和收盘价格计算， 在调整后的交易日按调整后的转股价格和收盘价格计算。如果出现转股价格向下 修正的情况，则上述连续三十个交易日须从转股价格调整之后的第一个交易日起 重新计算。 10、回售申报期内"健帆转债"暂停转股 11、"健帆转债"持有人有权选择是否进行回售，本次回售不具有强制性。 ...

Group 1 - The core viewpoint of the news highlights the current stock performance and valuation metrics of Jianfan Biological Technology Group Co., Ltd, indicating a recent increase in stock price and a low rolling PE ratio compared to the industry average [1][3] - As of March 31, 2025, the number of shareholders for Jianfan Biological has increased to 52,502, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The company specializes in the research, production, and sales of biomedical materials and high-tech medical devices, with a range of products including various blood purification devices and disinfectants [2] Group 2 - The latest financial results for the first quarter of 2025 show that Jianfan Biological achieved a revenue of 548 million yuan, representing a year-on-year decrease of 26.40%, and a net profit of 189 million yuan, down 33.71% from the previous year, with a gross profit margin of 80.74% [2] - The company ranks 52nd in the medical device industry based on its PE ratio of 26.63, while the industry average is 55.46 and the median is 37.74 [1][3] - Jianfan Biological has received multiple accolades, including recognition as a key high-tech enterprise under the National Torch Program and has established various research platforms, demonstrating its commitment to innovation and technology [2]

Group 1: Market Performance - The pharmaceutical sector showed strength in early trading on July 25, with the Biopharmaceutical ETF (159859) having a turnover rate exceeding 3.5% and a transaction volume of over 1.11 billion yuan, leading among its peers [1] - The Medical Devices ETF (159873) increased by 0.82% with a turnover rate over 8.1%, featuring stocks like Kangtai Medical hitting the daily limit [1] - The Innovation Drug ETF Tianhong (517380) rose by 0.79% with a turnover rate exceeding 1.8%, and its constituent stocks included Kanglong Chemical and WuXi Biologics, which saw significant gains [1] Group 2: ETF Characteristics - The Biopharmaceutical ETF (159859) closely tracks the National Index of Biopharmaceuticals (399441.SZ), covering various sectors such as innovative drugs, CXO, vaccines, and blood products, making it the largest and most liquid product in its category [1] - The Innovation Drug ETF Tianhong (517380) is the largest in the market, spanning the Shanghai, Shenzhen, and Hong Kong markets, and is the only ETF tracking the Hang Seng Shanghai-Shenzhen-Hong Kong Innovation Drug Select 50 Index, which has a cumulative weight of nearly 60% in its top ten constituents [2] Group 3: Industry Insights - Jianghai Securities emphasizes the importance of focusing on innovative drug companies with rich R&D pipelines and suggests investing in the entire innovative drug industry chain due to its potential for strong synergistic development [3] - Everbright Securities recommends focusing on two types of targets: those that have consistently been selected in centralized procurement and possess dual advantages in quality and cost, and innovative drug companies with rich R&D pipelines whose core products are entering medical insurance or are expected to be included in the innovative drug catalog [3]

Group 1 - The core business of the company is the research, production, and sales of biomaterials and high-tech medical devices, with major products including various blood purification devices and solutions [2] - As of the first quarter of 2025, the company reported a revenue of 548 million yuan, a year-on-year decrease of 26.40%, and a net profit of 189 million yuan, a year-on-year decrease of 33.71%, with a gross profit margin of 80.74% [2] - The company has received multiple national and provincial recognitions, including being designated as a key high-tech enterprise under the National Torch Program and a national technology innovation demonstration enterprise [2] Group 2 - The company's current rolling price-to-earnings (PE) ratio is 24.60, while the average PE ratio for the medical device industry is 51.83, and the industry median is 37.23 [1][3] - The total market capitalization of the company is 17.817 billion yuan, ranking it 52nd in the industry based on PE ratio [1][3] - As of the first quarter of 2025, there are 12 institutions holding shares in the company, with a total holding of approximately 62.5493 million shares valued at 1.633 billion yuan [1]

Company Overview - Jianfan Biological Technology Group Co., Ltd. specializes in the research, production, and sales of biomaterials and high-tech medical devices [2] - The main products include various blood perfusion devices, dialysis solutions, disinfectants, and blood purification equipment [2] - The company has received multiple accolades, including being recognized as a key high-tech enterprise under the National Torch Program and a national champion in manufacturing [2] Financial Performance - For Q1 2025, the company reported a revenue of 548 million yuan, a year-on-year decrease of 26.40% [2] - The net profit for the same period was 189 million yuan, down 33.71% year-on-year, with a gross profit margin of 80.74% [2] Market Position - As of July 7, the company's stock closed at 22.84 yuan, with a rolling price-to-earnings (PE) ratio of 25.19 times [1] - The average PE ratio for the medical device industry is 51.42 times, with a median of 37.44 times, placing Jianfan Biological at the 55th position in the industry ranking [1][3] Capital Flow - On July 7, the net outflow of main funds for Jianfan Biological was 14.63 million yuan, although there was a total inflow of 46.86 million yuan over the past five days [1]

债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 证券代码：300529 证券简称：健帆生物 公告编号：2025-049 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 健帆生物科技集团股份有限公司（以下简称"公司"）于 2025 年 7 月 3 日 召开第五届董事会第三十次会议和第五届监事会第二十一次会议，审议通过了 《关于放弃参股公司股权转让优先购买权暨关联交易的议案》，现将相关事项说 明如下： 一、本次交易情况概述 苏州健联医疗信息技术有限公司（以下简称"苏州健联"）系公司的参股公 司，公司持股 10.00%，珠海晴朗阳光投资管理企业（有限合伙）（以下简称"晴 朗阳光"）持股 90.00%。晴朗阳光拟向苏州煜坤医疗投资合伙企业（有限合伙） （以下简称"苏州煜坤"）转让其持有的苏州健联 20.00%股权，对应 200 万元 注册资本，出资款已全额实缴（以下简称"本次股权交易"）。结合公司整体战 略规划及实际经营情况，公司拟放弃上述转让股权的优先购买权。 本次股权交易的出让方晴朗阳光的实际控制人系公司控股股东、实际控制人 董凡，公司董 ...

Company Overview - Jianfan Biological Technology Group Co., Ltd. specializes in the research, production, and sales of biomaterials and high-tech medical devices [2] - The main products include various blood perfusion devices, dialysis solutions, disinfectants, and blood purification equipment [2] - The company has received multiple accolades, including being recognized as a key high-tech enterprise under the National Torch Program and a national champion in manufacturing [2] Financial Performance - As of the first quarter of 2025, the company reported revenue of 548 million yuan, a year-on-year decrease of 26.40% [2] - The net profit for the same period was 189 million yuan, down 33.71% year-on-year, with a gross profit margin of 80.74% [2] Market Position - The company's stock closed at 23.19 yuan, with a PE ratio of 25.57, marking a new low in 55 days [1] - The average PE ratio in the medical device industry is 51.05, with a median of 36.62, placing Jianfan Biological at the 56th position in the industry ranking [1][3] - The total market capitalization of the company is 18.52 billion yuan [1] Institutional Holdings - As of the first quarter of 2025, 12 institutions hold shares in Jianfan Biological, including 10 funds, with a total holding of approximately 62.55 million shares valued at 1.633 billion yuan [1]

证券代码：300529 证券简称：健帆生物 公告编号：2025-048 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 表决情况：赞成 3 票，反对 0 票，弃权 0 票，0 票回避。本议案表决通过。 三、备查文件 第五届监事会第二十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 健帆生物科技集团股份有限公司（以下简称"公司"）第五届监事会第二十 一次会议于 2025 年 7 月 3 日在公司会议室以现场会议及通讯表决的方式召开， 本次会议应出席监事 3 人，实际出席监事 3 人。本次会议通知提前以电子邮件及 电话通知等方式向全体监事送达，会议由监事会主席彭小红先生主持，会议的召 开符合《公司法》和《公司章程》的有关规定。 二、监事会会议审议情况 经与会监事认真讨论，审议并表决通过了以下议案： 1、审议通过了《关于放弃参股公司股权转让优先购买权暨关联交易的议案》 经审核，监事会认为：公司放弃参股公司优先认购权暨关联交易事项遵循了 公开、公平、自愿、诚信的原则，不存在利用关联关系输送利益，也不存 ...

| 证券代码：300529 | 证券简称：健帆生物 | 公告编号：2025-047 | | --- | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | | 健帆生物科技集团股份有限公司 第五届董事会第三十次会议决议公告 一、董事会会议召开情况 健帆生物科技集团股份有限公司（以下简称"公司"）第五届董事会第三十 次会议于 2025 年 7 月 3 日在公司会议室以现场会议及通讯表决的方式召开，本 次会议应出席董事 9 人，实际出席董事 9 人，符合《公司法》和《公司章程》的 有关规定。本次会议通知提前以电子邮件及电话通知等方式向全体董事送达。公 司董事长董凡先生召集和主持了本次会议，公司监事和部分高级管理人员列席了 会议。本次董事会的召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事认真讨论，审议并表决通过了以下议案： 1、审议通过了《关于放弃参股公司股权转让优先购买权暨关联交易的议案》 苏州健联医疗信息技术有限公司（以下简称"苏州健联"）系公司的参股公 司，公司持股 10.00%，珠海晴朗阳光投资管理企业（有限合伙）（以下简称"晴 朗阳光"）持股 ...

| 证券代码：300529 | 证券简称：健帆生物 公告编号：2025-049 | | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | 健帆生物科技集团股份有限公司 关于放弃参股公司股权转让优先购买权暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 健帆生物科技集团股份有限公司（以下简称"公司"）于 2025 年 7 月 3 日 召开第五届董事会第三十次会议和第五届监事会第二十一次会议，审议通过了 《关于放弃参股公司股权转让优先购买权暨关联交易的议案》，现将相关事项说 明如下： 一、本次交易情况概述 苏州健联医疗信息技术有限公司（以下简称"苏州健联"）系公司的参股公 司，公司持股 10.00%，珠海晴朗阳光投资管理企业（有限合伙）（以下简称"晴 朗阳光"）持股 90.00%。晴朗阳光拟向苏州煜坤医疗投资合伙企业（有限合伙） （以下简称"苏州煜坤"）转让其持有的苏州健联 20.00%股权，对应 200 万元 注册资本，出资款已全额实缴（以下简称"本次股权交易"）。结合公司整体战 略规划及实际经营情况，公司拟放弃上述 ...